30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Foghorn Therapeutics Inc. (FHTX)

Track

The most recent insider trading activity occurred on September 23, 2024. Carlos Costa, Chief People Officer, engaged in a series of planned sales totaling approximately $560,000. Earlier in September, Steven Bellon, Chief Scientific Officer, also made a planned sale of $190,000. Prior to these, Fanny Cavalie sold shares in March 2024.
Stock chart
Ticker: FHTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Costa Carlos
Chief People Officer
1 sale — total 8,716 USD
Planned sale 23 Sep 2024
Value US$3,468,062.97 | Price 418.58 | Shares 62,580
Planned sale 20 Sep 2024
Value US$2,431,210.27 | Price 252.39 | Shares 55,524
Planned sale 18 Sep 2024
Value US$116,318.70 | Price 10.05 | Shares 11,574
Planned sale 17 Sep 2024
Value US$103,130.88 | Price 10.04 | Shares 10,272
Planned sale 16 Sep 2024
Value US$4,000.00 | Price 10.00 | Shares 400
Proposed sale 16 Sep 2024
Value US$958,858.56 | Price 9.72 | Shares 98,648
Planned sale 9 Sep 2024
Value US$190,000.00 | Price 9.50 | Shares 20,000
Proposed sale 9 Sep 2024
Value US$150,600.00 | Price 7.53 | Shares 20,000
Sale 11 Mar 2024
Value US$72,133.60 | Price 6.56 | Shares 11,000
Sale 16 Aug 2023
Value US$2,568,200.25 | Price 8.25 | Shares 311,297
Proposed sale 16 Aug 2023
Value US$2,568,200.25 | Price 8.25 | Shares 311,297
Buy 27 Oct 2020
Value US$800,000.00 | Price 16.00 | Shares 50,000
Buy 27 Oct 2020
Value US$800,000.00 | Price 16.00 | Shares 50,000
Buy 27 Oct 2020
Value US$800,000.00 | Price 16.00 | Shares 50,000
Buy 27 Oct 2020
Value US$88,000.00 | Price 16.00 | Shares 5,500
Buy 27 Oct 2020
Value US$2,400,000.00 | Price 16.00 | Shares 150,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-09-24 2024-09-23 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
62,580 +37.0%
418.58
US$3,468,063 		62,580 +37.0% 418.58 US$3,468,063
2024-09-24 2024-09-20 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
55,524 +3.7%
252.39
US$2,431,210 		55,524 +3.7% 252.39 US$2,431,210
2024-09-20 2024-09-18 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
53,847 -15.9%
489.78
US$804,698 		53,847 -15.9% 489.78 US$804,698
2024-09-18 2024-09-17 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
10,272 -100.0%
10.04
US$103,131 		10,272 -100.0% 10.04 US$103,131
2024-09-18 2024-09-16 PlS Planned sale
Costa Carlos

Chief People Officer

Officer
400 -100.0%
10.00
US$4,000 		400 -100.0% 10.00 US$4,000
2024-09-16 2024-09-16 PrS Proposed sale
CARLOS COSTA

Officer

Officer
98,648
9.72
US$958,859 		98,648 9.72 US$958,859
2024-09-11 2024-09-09 PlS Planned sale
Bellon Steven F.

Chief Scientific Officer

Officer
20,000 -16.4%
9.50
US$190,000 		20,000 -16.4% 9.50 US$190,000
2024-09-09 2024-09-09 PrS Proposed sale
STEVEN BELLON

Officer

Officer
20,000
7.53
US$150,600 		20,000 7.53 US$150,600
2024-03-12 2024-03-11 S Sale
2.3
Cavalie Fanny

Chief Strategy/Bus Ops Officer

Officer
11,000 -12.6%
6.56
US$72,134 		11,000 -12.6% 6.56 US$72,134
2023-08-18 2023-08-16 S Sale
Agresta Samuel

Chief Medical Officer

Officer
311,297 -100.0%
8.25
US$2,568,200 		311,297 -100.0% 8.25 US$2,568,200
2023-08-16 2023-08-16 PrS Proposed sale
SAMUEL AGRESTA

Officer

Officer
311,297
8.25
US$2,568,200 		311,297 8.25 US$2,568,200
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +2.8%
16.00
US$800,000 		50,000 +2.8% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +3.5%
16.00
US$800,000 		50,000 +3.5% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.9
Flagship Ventures Fund V General Partner LLC
Large shareholder
50,000 +0.5%
16.00
US$800,000 		50,000 +0.5% 16.00 US$800,000
2020-10-29 2020-10-27 B Purchase
3.0
DECICCO CARL

Chief Scientific Officer

Officer
5,500 +2.2%
16.00
US$88,000 		5,500 +2.2% 16.00 US$88,000
2020-10-28 2020-10-27 B Purchase
3.0
Abu Dhabi Investment Authority

Former 10% Owner
150,000 +13.9%
16.00
US$2,400,000 		150,000 +13.9% 16.00 US$2,400,000
Explore more

More insider trading research around Foghorn Therapeutics Inc.

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America